How to Get Wegovy in Colorado

What Is Wegovy and Who Qualifies in Colorado?

Wegovy is FDA-approved semaglutide 2.4 mg, a once-weekly subcutaneous GLP-1 receptor agonist indicated for chronic weight management in adults with a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. Colorado residents follow the same federal eligibility criteria, and no state-specific restrictions alter who qualifies medically.

The Clinical Evidence Behind the Approval

The key STEP-1 trial (N=1,961) published in the New England Journal of Medicine showed that semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks compared with 2.4% in the placebo group (P<0.001) [1]. Roughly 86.4% of participants on semaglutide achieved at least 5% weight loss, versus 31.5% on placebo [1]. Those outcomes formed the core of Novo Nordisk's FDA submission.

The SELECT trial (N=17,604), also published in the New England Journal of Medicine, found that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% relative to placebo in adults with pre-existing cardiovascular disease and overweight or obesity, extending the drug's clinical rationale well beyond cosmetic weight loss [2].

BMI Thresholds and Comorbidity Documentation

Colorado prescribers, whether in-person or via telehealth, document BMI using a measured or self-reported height and weight. A comorbidity for the 27 kg/m² threshold requires a confirmed diagnosis in the medical record. Common qualifying comorbidities include:

• Hypertension (documented BP readings or current antihypertensive medication)
• Type 2 diabetes or prediabetes (HbA1c on file)
• Obstructive sleep apnea (sleep study or clinical diagnosis)
• Dyslipidemia (lipid panel showing LDL, HDL, or triglyceride abnormalities)

The FDA prescribing information lists these comorbidities explicitly, and insurers in Colorado use the same list when reviewing prior authorization requests [3].

How to Get a Wegovy Prescription in Colorado

Getting a Wegovy prescription in Colorado takes three steps: a qualifying medical visit, baseline labs, and (in most cases) a prior authorization submission to your insurer. The order may shift slightly by provider, but those three components appear in virtually every access pathway in the state.

Step 1: Schedule a Medical Visit (In-Person or Telehealth)

Colorado allows telehealth prescribing for controlled and non-controlled medications without a mandatory prior in-person visit, consistent with the state's telehealth parity law codified in C.R.S. § 10-16-123. Wegovy is not a controlled substance, so a synchronous audio-video visit with a licensed Colorado prescriber satisfies the prescribing requirement.

Any of the following licensed clinicians can legally write a Wegovy prescription in Colorado:

• Medical doctors (MD) and doctors of osteopathic medicine (DO)
• Nurse practitioners (NP) practicing under a collaborative agreement or full practice authority
• Physician assistants (PA) under supervision or a collaboration agreement per state law

Colorado granted nurse practitioners full practice authority, meaning an NP can independently prescribe Wegovy without physician co-signature, which expands telehealth access considerably [4].

Step 2: Complete Baseline Labs

Most Colorado prescribers and all telehealth platforms require a recent lab panel before the first dose. Standard pre-treatment labs include:

• Fasting glucose and HbA1c
• Comprehensive metabolic panel (CMP) including liver and kidney function
• Fasting lipid panel
• Thyroid-stimulating hormone (TSH)
• Complete blood count (CBC)

The TSH matters because the Wegovy FDA label carries a contraindication for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), the same warning noted in the FDA prescribing information for semaglutide injection [3]. A thyroid panel helps rule out pre-existing thyroid pathology before starting.

Labs drawn within the prior 6 to 12 months may be acceptable to some prescribers if the patient has no interval changes in health status. Results from a primary care office, urgent care, or a direct-to-consumer lab such as Quest or LabCorp are all accepted.

Step 3: Prior Authorization

The Endocrine Society's 2023 Clinical Practice Guideline on Obesity states: "Anti-obesity medications should be used as part of a comprehensive treatment plan that includes behavioral interventions and is individualized to the patient." [5] Colorado commercial insurers generally follow that framing, but they also layer on their own formulary criteria before approving Wegovy.

Common prior authorization requirements across Colorado commercial plans include:

• Documented BMI meeting threshold, confirmed within the past 12 months
• Evidence of a supervised diet and lifestyle program (typically 3 to 6 months)
• Absence of contraindications (MTC history, MEN 2, pancreatitis history)
• Prescriber attestation that the patient has not responded to prior weight-loss interventions

Colorado Medicaid (Health First Colorado) does not cover Wegovy for chronic weight management as of 2025. Coverage is available only when semaglutide is prescribed for type 2 diabetes under the Ozempic indication [6]. Patients on Medicaid pursuing Wegovy specifically must pay out of pocket or explore manufacturer assistance programs.

Wegovy Telehealth Colorado: How Online Prescribing Works

Telehealth is the fastest-growing access channel for Wegovy in Colorado. Several national and regional platforms hold Colorado prescribing licenses and have built intake workflows that compress the consult-to-prescription timeline.

What a Telehealth Visit Looks Like

A typical telehealth consult for Wegovy in Colorado runs 20 to 40 minutes over HIPAA-compliant video. The clinician reviews:

1. Medical history form submitted before the visit
2. Current medications (screening for drug interactions and contraindications)
3. Lab results (uploaded ahead of time or ordered after the consult)
4. Weight history and prior weight-loss attempts

If labs are ordered at the visit, the prescriber may issue a conditional prescription pending review of results. Some platforms write the prescription at the same visit if the patient uploads labs from within the past 6 months.

Telehealth Platform Considerations for Colorado Patients

Colorado's telehealth parity law requires that commercial insurers reimburse telehealth services at parity with in-person care for covered services [7]. Weight-management consultations, however, are not uniformly covered, so many patients pay a flat monthly or per-visit fee to the telehealth platform regardless of their insurance plan. Fees range from roughly $99 to $250 per month across major platforms operating in Colorado as of mid-2025.

When comparing platforms, Colorado patients should verify:

• The platform's prescribers hold active Colorado licenses (check with the Colorado Division of Professions and Occupations)
• The platform submits prior authorization on the patient's behalf
• The platform partners with Colorado-licensed pharmacies or ships from a licensed out-of-state pharmacy

Wegovy Pharmacies in Colorado: Retail, Mail-Order, and 503A Compounding

Wegovy can be dispensed by any pharmacy that stocks it. National chains including CVS, Walgreens, King Soopers, Costco, and Walmart pharmacies in Colorado carry Wegovy or can order it, though supply has been inconsistent since the drug's 2021 launch.

Retail and Mail-Order Pharmacies

The FDA reported Wegovy shortage resolutions beginning in late 2023 for the 0.25 mg and 0.5 mg starter doses, with higher dose strengths following into 2024 [8]. Colorado patients experiencing stock-outs at one chain can request a transfer to another retail pharmacy or use Novo Nordisk's pharmacy locator tool. Mail-order pharmacies (including Express Scripts, Optum Rx, and CVS Caremark) may have better sustained supply for patients enrolled in those pharmacy benefit plans.

503A Compounding Pharmacies in Colorado

Colorado-licensed 503A compounding pharmacies may legally compound semaglutide for individual patients under a valid prescription when the branded product is on the FDA drug shortage list or when a patient has a documented allergy to an excipient in the commercial product [9]. The FDA listed semaglutide injection as in shortage from 2022 through portions of 2024, which opened the 503A compounding window during that period [8].

As of early 2025, the FDA removed semaglutide from its shortage list for most formulations, which limits 503A compounding for most patients. The American Society of Health-System Pharmacists notes that once a drug is removed from the shortage list, 503A pharmacies must cease compounding that product for general distribution [10]. Colorado patients considering compounded semaglutide should confirm the current shortage status directly with the FDA before proceeding, as the regulatory window can shift.

Compounded semaglutide from a 503A pharmacy does not carry FDA approval and has not been evaluated in the same safety trials as Wegovy. The FDA issued safety communications in 2024 warning about adverse events reported from compounded semaglutide products, including dosing errors linked to different concentration formulations [8].

Cost Without Insurance

The list price for Wegovy in the United States is approximately $1,349 per month for the maintenance dose (2.4 mg). Novo Nordisk's savings card program reduces out-of-pocket cost to as low as $0 per month for eligible commercially insured patients and approximately $650 per month for uninsured patients who qualify [11]. Colorado patients without coverage can apply through Novo Nordisk's NovoCare patient assistance program at no cost to determine eligibility [11].

Transferring a Wegovy Prescription to Colorado

Patients moving to Colorado or switching pharmacies can transfer a Wegovy prescription from another state or another in-state pharmacy. Because Wegovy is not a Schedule II through V controlled substance, Colorado law permits a full transfer (including remaining refills) from one pharmacy to another. The receiving pharmacy contacts the originating pharmacy directly.

What You Need for a Transfer

• The name, address, and phone number of the originating pharmacy
• Your date of birth and the prescribing physician's name
• The original prescription date and refill count

If the prescription was written by an out-of-state provider whose license does not extend to Colorado, the receiving Colorado pharmacy may require a new prescription from a Colorado-licensed prescriber. Telehealth platforms can generate a new prescription during a brief follow-up visit, which many platforms offer at reduced or no charge for established patients.

Understanding the Dose Escalation Schedule

Novo Nordisk designed Wegovy around a structured four-step dose escalation to reduce gastrointestinal side effects, particularly nausea and vomiting, which were reported by 44% of participants in STEP-1 [1]. The schedule approved in the FDA label is:

| Weeks | Dose | |---|---| | 1 to 4 | 0.25 mg once weekly | | 5 to 8 | 0.5 mg once weekly | | 9 to 12 | 1.0 mg once weekly | | 13 to 16 | 1.7 mg once weekly | | 17 and beyond | 2.4 mg once weekly (maintenance) |

Some prescribers in Colorado extend each step by an extra 4 weeks for patients who experience persistent nausea, which the FDA label permits [3]. Patients should not attempt to self-escalate to the 2.4 mg maintenance dose early, as doing so was associated with higher rates of study discontinuation due to adverse events in STEP-1 [1].

Side Effects and Contraindications Colorado Patients Should Know

The most common side effects reported in STEP-1 and subsequent STEP trials are gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) in the semaglutide group versus lower rates in placebo [1]. Most GI events were mild to moderate and occurred during dose escalation.

Contraindications from the FDA Label

The FDA label for Wegovy lists the following absolute contraindications [3]:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known serious hypersensitivity reaction to semaglutide or any excipient

Warnings and Precautions

The label includes warnings for acute pancreatitis, acute gallbladder disease, hypoglycemia (particularly in patients on insulin or sulfonylureas), acute kidney injury, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase, and suicidal ideation [3]. Colorado prescribers completing a telehealth intake review these risk factors during the medical history portion of the visit.

A 2023 review in JAMA Internal Medicine examined pharmacovigilance data from the FDA Adverse Event Reporting System and found that GLP-1 receptor agonists were associated with reports of aspiration events during endoscopy and surgery, prompting several anesthesiology societies to recommend stopping GLP-1 agonists 1 to 2 weeks before elective procedures [12]. Colorado patients scheduled for surgery should inform both their surgeon and their Wegovy prescriber.

What Documentation Prior Authorization Requires in Colorado

Colorado commercial insurers vary in their prior authorization forms, but the content they request is largely standardized by the Academy of Managed Care Pharmacy framework. A complete prior authorization packet for Wegovy typically includes:

Clinical Documentation Package

• Office notes from the treating physician or NP documenting BMI, comorbidities, and weight history
• Lab results showing HbA1c, fasting glucose, and lipids within the past 12 months
• A signed letter of medical necessity from the prescriber
• Records of participation in a structured weight-loss program (diet counseling, behavioral therapy, or a commercial program such as WW or Noom documented in the chart)
• Attestation that the patient meets FDA labeled indications [3]

A 2022 analysis published in Obesity found that prior authorization for anti-obesity medications took a mean of 26 days to resolve across U.S. Commercial insurers, with 31% of initial requests denied and subsequently overturned on appeal at a rate of 54% [13]. Colorado patients denied on first submission should appeal with additional clinical documentation rather than abandoning the request.

Appeals in Colorado

Colorado's Division of Insurance regulates insurer conduct and allows patients to request an internal appeal within 60 days of a denial and an external independent medical review if the internal appeal fails. Patients can submit a complaint to the Colorado Division of Insurance if an insurer fails to respond to an appeal within statutory timeframes [14].

Timeline: How Long Until You Receive Wegovy in Colorado?

From initial telehealth consult to first injection, realistic timelines break down as follows:

• Day 0 to 3: Telehealth or in-person consult, lab order placed
• Day 1 to 7: Labs completed and reviewed by prescriber
• Day 3 to 10: Prescription written; prior authorization submitted to insurer
• Day 10 to 30: Prior authorization decision (mean 26 days per published data [13])
• Day 30 to 35: Prescription filled; mail-order delivery or retail pickup

Patients whose insurer does not require prior authorization (some high-deductible plans where the patient pays full cost, or plans with an open formulary) may receive Wegovy within 3 to 7 days of the consult. Patients on Colorado Medicaid seeking Wegovy for weight management will not receive coverage and must arrange self-pay before the prescription can be filled.